| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Graft Occlusion, Vascular | D006083 | 11 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
| Neovascularization, Pathologic | D009389 | 39 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Dermatitis, Contact | D003877 | 59 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Autoimmune Diseases | D001327 | 27 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Genital Diseases, Female | D005831 | 7 associated lipids |
| Mouth Diseases | D009059 | 5 associated lipids |
| Meningococcal Infections | D008589 | 3 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wilson CH et al. | Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. | 2004 | Ann. Transplant. | pmid:15478912 |
| Foroncewicz B et al. | A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. | 2013 | Ann. Transplant. | pmid:23896824 |
| Arreola-Guerra JM et al. | Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. | 2016 | Ann. Transplant. | pmid:26879833 |
| Mocchegiani F et al. | Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. | 2014 | Ann. Transplant. | pmid:25347718 |
| Bäckman L and Persson CA | An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. | 2014 | Ann. Transplant. | pmid:24637379 |
| Girman P et al. | The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. | 2001 | Ann. Transplant. | pmid:11803619 |
| Steinebrunner N et al. | Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. | 2014 | Ann. Transplant. | pmid:24457606 |
| Wu YJ et al. | Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:26782179 |
| Czubkowski P et al. | Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation. | 2014 | Ann. Transplant. | pmid:25409773 |
| Aguiar D et al. | Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. | 2017 | Ann. Transplant. | pmid:28461684 |
| Roan JN et al. | Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. | 2013 | Ann. Transplant. | pmid:23792500 |
| Tanaka T et al. | Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. | 2013 | Ann. Transplant. | pmid:23792533 |
| Ueda K et al. | Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. | 2014 | Ann. Transplant. | pmid:24535029 |
| Augusto JF et al. | Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. | 2013 | Ann. Transplant. | pmid:23872516 |
| Miyata Y et al. | Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. | 2016 | Ann. Transplant. | pmid:27503662 |
| Mizuno S et al. | Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. | 2013 | Ann. Transplant. | pmid:23845965 |
| Kuypers DR | Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. | 2008 | Ann. Transplant. | pmid:18806728 |
| Basu A et al. | Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. | 2011 Jul-Sep | Ann. Transplant. | pmid:21959503 |
| Fukazawa K et al. | Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. | 2011 Jul-Sep | Ann. Transplant. | pmid:21959523 |
| Zegarska J et al. | Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. | 2015 | Ann. Transplant. | pmid:26313036 |
| Bułanowski M et al. | Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. | 2012 Jul-Sep | Ann. Transplant. | pmid:23018257 |
| Schmid S et al. | Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection. | 2014 | Ann. Transplant. | pmid:25123847 |
| Baran DA and Galin ID | "One size fits all": immunosuppression in cardiac transplantation. | 2003 | Ann. Transplant. | pmid:12848376 |
| Remiszewski P et al. | Orthotopic liver transplantation for acute liver failure resulting from "acute fatty liver of pregnancy". | 2003 | Ann. Transplant. | pmid:15114933 |
| Dedinská I et al. | Waist circumference as an independent risk factor for NODAT. | 2015 | Ann. Transplant. | pmid:25791039 |
| Eguchi S et al. | Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. | 2007 | Ann. Transplant. | pmid:18344932 |
| Garaix F et al. | Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. | 2018 | Ann. Transplant. | pmid:30093607 |
| WÅ‚odarczyk Z et al. | Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. | 2002 | Ann. Transplant. | pmid:12465429 |
| Matia I et al. | Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. | 2014 | Ann. Transplant. | pmid:24815872 |
| Gardiner KM et al. | Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. | 2016 | Ann. Transplant. | pmid:26729299 |
| Provenzani A et al. | The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. | 2009 Jan-Mar | Ann. Transplant. | pmid:19289993 |
| Urbanowicz T et al. | Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. | 2014 | Ann. Transplant. | pmid:24949728 |
| Tang JT et al. | A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. | 2018 | Ann. Transplant. | pmid:29735966 |
| Fuchs U et al. | Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. | 2014 | Ann. Transplant. | pmid:24953848 |
| Abdel Halim M et al. | Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. | 2010 Jan-Mar | Ann. Transplant. | pmid:20305320 |
| Wu P et al. | Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. | 2011 Jan-Mar | Ann. Transplant. | pmid:21436775 |
| Foroncewicz B et al. | Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis. | 2014 | Ann. Transplant. | pmid:25163829 |
| Bösmüller C et al. | Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. | 2012 | Ann. Transplant. | pmid:23274323 |
| Olczak-Kowalczyk D et al. | The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. | 2012 | Ann. Transplant. | pmid:23274327 |
| Zakliczyński M et al. | Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. | 2005 | Ann. Transplant. | pmid:16218032 |
| Mahalati K and Kahan BD | Pharmacological surrogates of allograft outcome. | 2000 | Ann. Transplant. | pmid:11217202 |
| Garlicki M et al. | Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. | 2006 | Ann. Transplant. | pmid:17025026 |
| Ruangkanchanasetr P et al. | Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. | 2016 | Ann. Transplant. | pmid:27980321 |
| Malinowski M et al. | The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. | 2009 Apr-Jun | Ann. Transplant. | pmid:19487793 |
| Kishida N et al. | Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27956735 |
| Duvoux C et al. | Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. | 2015 | Ann. Transplant. | pmid:25588713 |
| Albano L et al. | Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. | 2016 | Ann. Transplant. | pmid:27122116 |
| Thölking G et al. | Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27003330 |
| Snell GI et al. | Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. | 2013 | Ann. Transplant. | pmid:23921892 |
| Wyzgał J et al. | Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. | 2007 | Ann. Transplant. | pmid:18173063 |